Sarcolemmal targeting of nNOSμ improves contractile function of mdx muscle.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Human Molecular Genetics

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1093/hmg/ddv466PMID 26604149PMCID PMC4690500
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Loss of nNOS inhibits compensatory muscle hypertrophy and exacerbates inflammation and eccentric contraction-induced damage in mdx mice.

  2015cited by this paper
• EUK-134 ameliorates nNOSμ translocation and skeletal muscle fiber atrophy during short-term mechanical unloading.

  2014cited by this paper
• Sildenafil reduces respiratory muscle weakness and fibrosis in the mdx mouse model of Duchenne muscular dystrophy

  2012cited by this paper
• Age‐related loss of nitric oxide synthase in skeletal muscle causes reductions in calpain S‐nitrosylation that increase myofibril degradation and sarcopenia

  2012cited by this paper
• Fatigue and Muscle Atrophy in a Mouse Model of Myasthenia Gravis Is Paralleled by Loss of Sarcolemmal nNOS

  2012cited by this paper
• α2 and α3 helices of dystrophin R16 and R17 frame a microdomain in the α1 helix of dystrophin R17 for neuronal NOS binding

  2012cited by this paper
• Loss of sarcolemmal nNOS is common in acquired and inherited neuromuscular disorders

  2011cited by this paper
• Daily Treatment with SMTC1100, a Novel Small Molecule Utrophin Upregulator, Dramatically Reduces the Dystrophic Symptoms in the mdx Mouse

  2011cited by this paper
• Drug Discovery for Duchenne Muscular Dystrophy via Utrophin Promoter Activation Screening

  2011cited by this paper
• Neuronal NOS is dislocated during muscle atrophy in amyotrophic lateral sclerosis.

  2010cited by this paper
• Sarcolemmal nNOS anchoring reveals a qualitative difference between dystrophin and utrophin

  2010cited by this paper
• Golgi and sarcolemmal neuronal NOS differentially regulate contraction-induced fatigue and vasoconstriction in exercising mouse skeletal muscle.

  2010cited by this paper
• Skeletal muscle glucose uptake during contraction is regulated by nitric oxide and ROS independently of AMPK.

  2010cited by this paper
• Biglycan recruits utrophin to the sarcolemma and counters dystrophic pathology in mdx mice

  2010cited by this paper
• Stretch-induced membrane damage in muscle: comparison of wild-type and mdx mice.

  2010cited by this paper
• Sarcolemma-localized nNOS is required to maintain activity after mild exercise

  2008cited by this paper
• Functional Deficits in nNOSμ-Deficient Skeletal Muscle: Myopathy in nNOS Knockout Mice

  2008cited by this paper
• NO production results in suspension-induced muscle atrophy through dislocation of neuronal NOS.

  2007cited by this paper
• SKELETAL MUSCLE FUNCTION: ROLE OF IONIC CHANGES IN FATIGUE, DAMAGE AND DISEASE

  2004cited by this paper
• Expression of a NOS transgene in dystrophin-deficient muscle reduces muscle membrane damage without increasing the expression of membrane-associated cytoskeletal proteins.

  2004cited by this paper
• Mitochondrial biogenesis: which part of "NO" do we understand?

  2003cited by this paper
• Expression of a muscle‐specific, nitric oxide synthase transgene prevents muscle membrane injury and reduces muscle inflammation during modified muscle use in mice

  2003cited by this paper
• Loss of sarcolemma nNOS in sarcoglycan‐deficient muscle

  2002cited by this paper
• A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice

  2001cited by this paper
• The dystrophin–glycoprotein complex, cellular signaling, and the regulation of cell survival in the muscular dystrophies

  2001cited by this paper
• Physiology of nitric oxide in skeletal muscle.

  2001cited by this paper
• Functional muscle ischemia in neuronal nitric oxide synthase-deficient skeletal muscle of children with Duchenne muscular dystrophy.

  2000cited by this paper
• Assembly of the Dystrophin-Associated Protein Complex Does Not Require the Dystrophin Cooh-Terminal Domain

  2000cited by this paper
• The NO way to increase muscular utrophin expression?

  2000cited by this paper
• nNOS and eNOS modulate cGMP formation and vascular response in contracting fast-twitch skeletal muscle.

  2000cited by this paper
• Nitric oxide and l-arginine cause an accumulation of utrophin at the sarcolemma: a possible compensation for dystrophin loss in Duchenne muscular dystrophy.

  1999cited by this paper
• Impaired metabolic modulation of alpha-adrenergic vasoconstriction in dystrophin-deficient skeletal muscle.

  1998cited by this paper
• Activation of the cardiac calcium release channel (ryanodine receptor) by poly-S-nitrosylation.

  1998cited by this paper
• Expression of full-length utrophin prevents muscular dystrophy in mdx mice

  1998cited by this paper
• Expression of Nitric Oxide Synthase in Skeletal Muscle: A Novel Role for Nitric Oxide as a Modulator of Insulin Action

  1997cited by this paper
• Regulation of neuronal nitric oxide synthase through alternative transcripts.

  1997cited by this paper
• Differential Association of Syntrophin Pairs with the Dystrophin Complex

  1997cited by this paper
• Research in Health Care

  1996cited by this paper
• Nitric oxide synthase I (NOS-I) is deficient in the sarcolemma of striated muscle fibers in patients with Duchenne muscular dystrophy, suggesting an association with dystrophin.

  1996cited by this paper
• Interaction of nitric oxide synthase with the postsynaptic density protein PSD-95 and alpha1-syntrophin mediated by PDZ domains.

  1996cited by this paper
• Neuronal Nitric-oxide Synthase-, an Alternatively Spliced Isoform Expressed in Differentiated Skeletal Muscle (*)

  1996cited by this paper
• Reversible inactivation of calpain isoforms by nitric oxide.

  1995cited by this paper
• Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy.

  1995cited by this paper
• The c-K-ras gene and human cancer (review).

  1987cited by this paper
• Multiple 5'-flanking regions of the human alpha-skeletal actin gene synergistically modulate muscle-specific expression

  1987cited by this paper

• Histone deacetylases in Duchenne muscular dystrophy: a role in the mechanism of disease and a target for inhibition

  2025cites this paper
• Curcumin as a Natural Therapeutic Agent in Exercise-Induced Muscle Injury and Recovery

  2025cites this paper
• Metformin ablates high fat diet-induced skeletal muscle hypertrophy and elevation of sarcolemmal GLUT4 when feeding is initiated in young adult male mice

  2025cites this paper
• Impaired hydrogen sulfide biosynthesis underlies eccentric contraction–induced force loss in dystrophin-deficient skeletal muscle

  2025cites this paper
• Why is early-onset atrial fibrillation uncommon in patients with Duchenne Muscular Dystrophy? Insights from the mdx mouse.

  2024cites this paper
• Pathophysiology and Management of Fatigue in Neuromuscular Diseases

  2023cites this paper
• Modulating fast skeletal muscle contraction protects skeletal muscle in animal models of Duchenne muscular dystrophy

  2023cites this paper
• Episodic Binge-like Ethanol Reduces Skeletal Muscle Strength Associated with Atrophy, Fibrosis, and Inflammation in Young Rats

  2023cites this paper
• Promising therapeutic approaches of utrophin replacing dystrophin in the treatment of Duchenne muscular dystrophy

  2022cites this paper
• Assessment of Muscle Function Following hiPSC‐Derived Myoblast Transplantation in Dystrophic Mice

  2022cites this paper
• Dose-Escalation Study of Systemically Delivered rAAVrh74.MHCK7.micro-dystrophin in the mdx Mouse Model of Duchenne Muscular Dystrophy

  2021cites this paper
• The Donnan-dominated resting state of skeletal muscle fibers contributes to resilience and longevity in dystrophic fibers

  2021cites this paper
• Role of Matricellular CCN Proteins in Skeletal Muscle: Focus on CCN2/CTGF and Its Regulation by Vasoactive Peptides

  2021cites this paper
• Soluble guanylate cyclase stimulation mitigates skeletal and cardiac muscle dysfunction in a mdx model of Duchenne muscular dystrophy

  2021cites this paper
• Master Regulators of Muscle Atrophy: Role of Costamere Components

  2021cites this paper
• Role of hypoxia in skeletal muscle fibrosis: Synergism between hypoxia and TGF-β signaling upregulates CCN2/CTGF expression specifically in muscle fibers.

  2020cites this paper
• Donnan dominated ion homeostasis and the longevity of ischemic Na+-loaded dystrophic skeletal muscle

  2020cites this paper
• Dystrophin R16/17 protein therapy restores sarcolemmal nNOS in trans and improves muscle perfusion and function

  2019cites this paper
• Neuronal nitric oxide synthase (nNOS) splice variant function: Insights into nitric oxide signaling from skeletal muscle.

  2019cites this paper
• Regulation of fibrosis in muscular dystrophy.

  2018cites this paper
• Perspective: Spectrin-Like Repeats in Dystrophin Have Unique Binding Preferences for Syntrophin Adaptors That Explain the Mystery of How nNOSμ Localizes to the Sarcolemma

  2018cites this paper
• Mice lacking &agr;‐, &bgr;1‐ and &bgr;2‐syntrophins exhibit diminished function and reduced dystrophin expression in both cardiac and skeletal muscle

  2018cites this paper
• Sarcolemmal loss of active nNOS (Nos1) is an oxidative stress‐dependent, early event driving disuse atrophy

  2018cites this paper
• Syntrophin binds directly to multiple spectrin-like repeats in dystrophin and mediates binding of nNOS to repeats 16–17

  2018cites this paper
• Relation of nNOS isoforms to mitochondrial density and PGC-1alpha expression in striated muscles of mice.

  2018cites this paper
• Non-Glycanated Biglycan and LTBP4: Leveraging the extracellular matrix for Duchenne Muscular Dystrophy therapeutics.

  2018cites this paper
• Loss of peroxiredoxin-2 exacerbates eccentric contraction-induced force loss in dystrophin-deficient muscle

  2018cites this paper
• Dystrophin R16/17-syntrophin PDZ fusion protein restores sarcolemmal nNOSμ

  2018cites this paper
• Role of neuronal nitric oxide synthase (nNOS) in Duchenne and Becker muscular dystrophies - Still a possible treatment modality?

  2018cites this paper
• Characterising and evaluating the efficacy of metabolic therapies for the treatment of Duchenne Muscular Dystrophy

  2017cites this paper
• Subcellular Targeting of Nitric Oxide Synthases Mediated by Their N-Terminal Motifs.

  2017cites this paper
• Therapeutic strategies to address neuronal nitric oxide synthase deficiency and the loss of nitric oxide bioavailability in Duchenne Muscular Dystrophy

  2017cites this paper
• A phase 3 randomized placebo-controlled trial of tadalafil for Duchenne muscular dystrophy

  2017cites this paper
• Blockade of Bradykinin receptors worsens the dystrophic phenotype of mdx mice: differential effects for B1 and B2 receptors

  2017cites this paper
• Validation of ultrasonography for non‐invasive assessment of diaphragm function in muscular dystrophy

  2016cites this paper